Mariner, LLC Savara Inc Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Savara Inc stock. As of the latest transaction made, Mariner, LLC holds 12,157 shares of SVRA stock, worth $40,847. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,157

Previous 12,836 5.29%

Holding current value

$40,847

Previous $51,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$3.96 - $5.07 $2,688 - $3,442	-679 Reduced 5.29%	12,157 $51,000
Q2 2024 Aug 13, 2024	SELL	$3.66 - $5.34 $11,924 - $17,397	-3,258 Reduced 20.24%	12,836 $51,000
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $15,838 - $21,130	3,780 Added 30.7%	16,094 $80,000
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $39,158 - $60,338	12,314 New	12,314 $57,000
Q3 2022 Nov 10, 2022	BUY	$1.36 - $1.88 $63,512 - $87,796	46,700 New	46,700 $72,000
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $140,997 - $195,961	-119,489 Closed	0 $0
Q2 2021 Aug 24, 2021	BUY	$1.51 - $2.29 $28,907 - $43,839	19,144 Added 19.08%	119,489 $203,000
Q1 2021 May 07, 2021	BUY	$1.17 - $2.33 $117,403 - $233,803	100,345 New	100,345 $209,000
Q3 2020 Nov 13, 2020	SELL	$1.09 - $2.21 $119,395 - $242,076	-109,537 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.8 - $3.05 $396 - $671	220 Added 0.2%	109,537 $273,000
Q1 2020 May 14, 2020	BUY	$1.91 - $4.08 $122,612 - $261,915	64,195 Added 142.27%	109,317 $232,000
Q4 2019 Feb 13, 2020	BUY	$0.71 - $4.91 $32,036 - $221,549	45,122 New	45,122 $202,000
Q3 2019 Nov 13, 2019	SELL	$2.16 - $3.2 $48,384 - $71,680	-22,400 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $16,353 - $80,730	6,900 Added 44.52%	22,400 $53,000
Q4 2018 Feb 13, 2019	BUY	$6.27 - $10.92 $97,185 - $169,260	15,500 New	15,500 $117,000

Others Institutions Holding SVRA

# of Institutions

129

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account